how were glp-1 drugs discovered medications get at the heart of addiction: study – WashU Medicine How GLP-1 Receptor Agonists Evolved

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer

This is just a glimpse of the GLP-1 insights available to CivicScience clients

Increasingly, AITD coexists with metabolic disorders such as obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting an interplay between immune dysregulation and metabolic health

This review focuses on how GLP-1RAs impact lipid-related outcomes

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation